Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01082289 · ClinicalTrials.gov registry record · Phase 1
Digoxin Drug-Drug Interaction With Lurasidone HCl
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01082289 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 24 participants.
The verdict
NCT01082289, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the pharmacokinetic profile of digoxin when administered alone and when administered with repeated dose of lurasidone 120mg.
Interventions
- DRUG Lurasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-09 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01082289
The ClinicalTrials.gov registry entry for NCT01082289 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lurasidone is the first listed.
NCT01082289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01082289 about?
NCT01082289 is a clinical study titled "Digoxin Drug-Drug Interaction With Lurasidone HCl". The objective of this study is to evaluate the pharmacokinetic profile of digoxin when administered alone and when administered with repeated dose of lurasidone 120mg.
What is the current status of trial NCT01082289?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2008-09. Estimated completion is 2008-10.
What interventions are being tested in trial NCT01082289?
The interventions under investigation include: Lurasidone (DRUG).
Who is sponsoring clinical trial NCT01082289?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.